Manas AI Announces $26M Seed Extension and the Appointment of Ujjwal Singh as Co-Founder and Chief Technology Officer

Audio By Carbonatix

NEW YORK--(BUSINESS WIRE)--Sep 23, 2025--

Manas AI, a full-stack, AI native drug discovery and development company, today announced the closing of a $26M Seed Extension and the addition of its new Co-Founder and Chief Technology Officer, Ujjwal Singh.

Manas AI was founded to overcome the critical inefficiencies of traditional drug development. By uniting world-class biomedical expertise and next generation AI capabilities, the company is pioneering a new paradigm of faster, cheaper, and more precise medicines.

Manas AI will utilize the new funding to accelerate the development of its drug discovery foundational models and advance its current therapeutic campaigns. Manas AI will also utilize funds to continue to expand its team of premier interdisciplinary individuals, with new additions headed by Ujjwal Singh.

Singh joins Manas AI having most recently served as Chief Technology and Product Officer at Multiverse. He previously held the role of Head of Workplace at Meta, following a distinguished tenure at Google where he drove significant product innovation. At Google, Singh was a Partner at the internal incubator, Area 120, and as Senior Director of Engineering, he founded and launched Google Hangouts. He also spearheaded the engineering efforts that expanded YouTube into dedicated platforms like YouTube Kids, Music, and Gaming.

“We are incredibly excited to welcome Ujjwal Singh as both a Co-Founder and Chief Technology Officer,” said Dr. Siddhartha Mukherjee, CEO and Co-Founder of Manas AI. “Ujjwal’s extensive AI and productization background perfectly complement the AI-native, scalable design of Manas’ vision. Ujjwal will not only make an impact on our cutting-edge AI capabilities but also as an experienced and visionary leader in the Co-Founder role.”

“Manas AI’s mission to usher in a new era of medicine—one defined by accelerated discovery and highly targeted therapies—deeply resonates with me,” said Singh. “Together with Reid Hoffman, Dr. Siddhartha Mukherjee, and the rest of the remarkable leadership team, I believe we can build a truly meaningful company that harnesses and deploys the most impactful aspects of the AI revolution we are witnessing.”

“It is excellent to work with Ujjwal again. Ujjwal is an amazing technologist, who brings the experience of many scale AI projects to Manas’ mission to transform the drug discovery process,” said Reid Hoffman, Co-Founder of Manas AI, Inflection AI, and LinkedIn.

Manas AI’s Seed Extension follows a $24.6M Seed Round announced in January of this year led by General Catalyst and Reid Hoffman. The seed extension also includes The General Partnership, Wisdom Ventures, Blitzscaling Ventures, Westbound Equity Partners, Mosaic Ventures, and a number of individuals.

About Manas AI
Co-founded by Dr. Siddhartha Mukherjee, Reid Hoffman, and Ujjwal Singh, Manas AI builds and uses neuro-symbolic, science-based foundational models to discover and bring transformative medicines to market. Manas AI is headquartered in New York City, NY.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250923943644/en/

Aria Finger:[email protected]

KEYWORD: UNITED STATES NORTH AMERICA NEW YORK

INDUSTRY KEYWORD: HEALTH TECHNOLOGY SOFTWARE GENERAL HEALTH ARTIFICIAL INTELLIGENCE PHARMACEUTICAL

SOURCE: Manas AI

Copyright Business Wire 2025.

PUB: 09/23/2025 10:05 AM/DISC: 09/23/2025 10:04 AM

http://www.businesswire.com/news/home/20250923943644/en